Pure heart rate reduction: Further perspectives in heart failure

European Heart Journal, Supplement

Volumn 9, Issue F, 2007, Pages

  Swedberg, Karl ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Heart failure; Heart rate; If current; Left ventricular dysfunction

Indexed keywords

EID: 66749127473     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sum031     Document Type: Review

References (30)

1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-1140.
2. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE. Prevalence of heart failure and left ventricular dysfunction in the general population. Eur Heart J 1999;20:447-455.
3. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J, for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-463.
4. Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail 1999;1:229-241.
5. Jouven X, Empana JP, Buyck JF, Canoui-Poitrine F, Kane A et al. Resting heart rate and its changes over years as a risk factor for mortality in the general population: the Paris Prospective Study I (Abstract Suppl.). Eur Heart J 2006;27:303.
6. Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Elliott P, Ueshima H. Resting heart rate and cause-specific death in a 16.5-year cohort study of the Japanese general population. Am Heart J 2004;147:1024-1032.
7. Palatini P. Heart rate: a strong predictor of mortality in subjects with coronary artery disease. Eur Heart J 2005;26:943-945.
8. Deedwania P, Carbajal E, Dietz R, Mukherjee R, Van Mieghem Wet al. Heart rate is a powerful predictor of mortality in Post-AMI patients with heart failure: results from the EPHESUS trial (Abstract Suppl.). Eur Heart J 2006;27:590.
9. Kjekshus J. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol 1986;157(Suppl. F):43F-49F.
10. Holmberg S, Varnauskas E. Coronary circulation during pacing-induced tachycardia. Acta Med Scand 1971;190:481-490.
11. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P et al. Bucindolol Investigators. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-1642.
12. Demopoulos L, Yeh M, Gentilucci M, Testa M, Bijou R, Katz SD, Mancini D, Jones M, Le Jemtel TH. Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. Circulation 1997;95:1764-1767.
13. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
14. Goldstein S, Fagerberg B, Hjalmarson A, Kjekshus J, Waagstein F, Wedel H, Wikstrand J, MERIT-HF Study Group. Metoprolol controlled release/extended release in patients with severe heart failure. Analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001;38:932-938.
15. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomizer Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658.
16. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999;33:916-923.
17. Cleland JG, McGowan J, Clark A, Freemantle N. The evidence for beta blockers in heart failure. BMJ 1999;318:824.
18. Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation 2000;102:484.
19. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, Pochmalicki G, Dargie H. Heart rate and cardiac rhythm relationships with bisoprolol benefit in heart failure in CIBIS II trial. Circulation 2001;103:1428-1433.
20. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, DiLenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, Charlesworth A, Poole-Wilson PA. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 2005;26:2259-2268.
21. Thackray SD, Ghosh JM, Wright GA, Witte KK, Nikitin NP, Kaye GC, Clark AL, Tweddel A, Cleland JG. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 2006;152:e9-e13.
22. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999;1(Suppl. H):H64-H69.
23. Mc Murray J, Swedberg K. Treatment of chronic heart failure: a comparison between major guidelines. Eur Heart J 2006;27:1773-1777.
24. Butler J, Khadim G, Belue R, Chomsky D, Dittus RS, Griffin M, Wilson JR. Tolerability to beta-blocker therapy among heart failure patients in clinical practice. J Card Fail 2003;9:203-209.
25. f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109: 1674-1679.
26. Lucats L, Ghaleh B, Colin P, Monnet X, Bize A, Berdeaux A. Heart rate reduction by inhibition of If or by β-blockade has different effects on postsystolic wall thickening. British J Pharmacol 2007;150:335- 341.
27. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003;100:149-155.
28. Jondeau G, Korewicki J, Vasiliauskas D. Effect of ivabradine in patients with left ventricular systolic dysfunction and coronary artery disease (Abstract 2637). Eur Heart J 2004;25(Suppl.):451.
29. De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Revera M, Campana C, Tavazzi L. Ivabradine infusion in patients with severe heart failure is safe, reduces heart rate and increases left ventricular stroke volume and systolic work (Abstract Suppl.). Eur Heart J 2006;27:330.
30. Current controlled trials. ISRCTN70429960: Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study [online]. Available from URL: http://www.controlledtrials.com/ISRCTN70429960/ivabradine.